Catalog # MA1810
Quantity:
TESTED APPLICATIONS | DILUTION |
---|---|
Flow Cytometry (Flow) | 0.5 µg/test |
Inhibition Assays (IA) | Assay-dependent |
Immunocytochemistry (ICC/IF) | 1:10-1:100 |
PUBLISHED APPLICATIONS | |
---|---|
Functional Assay (FN) | See 2 publications below |
Neutralization (Neu) | See 23 publications below |
Inhibition Assays (IA) | See 1 publications below |
Flow Cytometry (Flow) | See 8 publications below |
Immunohistochemistry (IHC) | See 1 publications below |
Species reactivity | Human |
Published species | Hamster, Human, Mouse |
Host / Isotype | Mouse / IgG1 |
Class | Monoclonal |
Type | Antibody |
Clone | TS1/18 |
Immunogen | Human Beta 2 Integrin |
Conjugate | Unconjugated |
Form | Liquid |
Concentration | 1 mg/mL |
Purification | Protein G |
Storage buffer | PBS |
Contains | no preservative |
Storage conditions | -20°C |
RRID | AB_223514 |
MA1810 targets CD18 in FACS, IA, and ICC/IF applications and shows reactivity with Human samples. This product has been tested for endotoxins by limulus amoebocyte lysate (LAL) assay and contains an endotoxin concentration of less than or equal to 10 endotoxin units per milligram (EU/mg).
The MA1810 immunogen is human Beta 2 Integrin.
MA1810 detects CD18 which has a predicted molecular weight of approximately 83 kDa.
CD18 integrin beta 2 subunit is a 90 kDa type I transmembrane protein expressed on all leucocytes. CD18 can combine with integrin molecules CD11a-c to form heterodimers at the cell surface, and these heterodimers are known to participate in the process of cell adhesion as well as cell-surface mediated signaling. CD18 forms heterodimers with four types of CD11 molecule to constitute leukocyte (beta2) integrins: alphaLbeta2 (CD11a/CD18, LFA-1), alphaMbeta2 (CD11b/CD18, Mac-1, CR3), alphaXbeta2 (CD11c/CD18) and alphaDbeta2 (CD11d/CD18). In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits, and these integrins are essential for proper leukocyte migration, mediating intercellular contacts. Absence of CD18 leads to leukocyte adhesion deficiency-1, severe reduction of CD18 expression leads to the development of a psoriasiform skin disease. CD18 is also a target of Mannheimia (Pasteurella) haemolytica leukotoxin and is sufficient to mediate leukotoxin-mediated cytolysis. Defects in the CD18 gene are the cause of leukocyte adhesion deficiency type I (LAD1). Two transcript variants encoding the CD18 protein have been identified.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: CD18; cell surface adhesion glycoprotein (LFA-1/CR3/P150,959 beta subunit precursor); Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta; complement component 3 receptor 3 and 4 subunit; complement receptor C3 beta-subunit; Complement receptor C3 subunit beta; integrin beta chain, beta 2; Integrin beta-2; integrin, beta 2 (complement component 3 receptor 3 and 4 subunit); leukocyte cell adhesion molecule CD18; leukocyte-associated antigens CD18/11A, CD18/11B, CD18/11C
Gene Aliases: CD18; ITGB2; LAD; LCAMB; LFA-1; MAC-1; MF17; MFI7
UniProt ID: (Human) P05107
Entrez Gene ID: (Human) 3689
Molecular Function:
integrin
If an Invitrogen™ antibody doesn’t perform as described on our website or datasheet, we’ll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.